Abstract
Ketamine, a non-competitive N-methyl-D-aspartate receptor (NMDAR) antagonist, has been employed clinically as an intravenous anesthetic since the 1970s. More recently, ketamine has received attention for its rapid antidepressant effects and is actively being explored as a treatment for a wide range of neuropsychiatric syndromes. In model systems, ketamine appears to display a combination of neurotoxic and neuroprotective properties that are context dependent. At anesthetic doses applied during neurodevelopmental windows, ketamine contributes to inflammation, autophagy, apoptosis, and enhances levels of reactive oxygen species. At the same time, subanesthetic dose ketamine is a powerful activator of multiple parallel neurotrophic signaling cascades with neuroprotective actions that are not always NMDAR-dependent. Here, we summarize results from an array of preclinical studies that highlight a complex landscape of intracellular signaling pathways modulated by ketamine and juxtapose the somewhat contrasting neuroprotective and neurotoxic features of this drug.
Introduction
Over the past several years, ketamine has garnered significant interest as a novel therapeutic within the research and lay/media communities for its efficacy as a rapidly acting antidepressant. In March 2019, the United States Food and Drug Administration approved esketamine nasal spray as an adjunct therapeutic for treatment-resistant depression (; ; ). As ketamine infusion protocols gradually become integrated into mainstream psychiatry practices (), a large body of preclinical research, encompassing a range of model systems, has shed light on the complex pharmacodynamic landscape of ketamine, which extends well beyond N-methyl-D-aspartate receptor (NMDAR) antagonism. A growing body of research seeks to identify one or more biologically active metabolites of ketamine () or agents with similar pharmacodynamic properties () that may avoid psychotomimetic and cardiovascular side effects (). As clinical protocols for repetitive ketamine treatments continue to evolve, delineating the long-term safety profile of ketamine administration remains a work in progress. In this review, we summarize a body of basic science literature to provide a forecast about ketamine’s potential as a neuroprotective agent (defined as a treatment that promotes glial/neuronal health during adversity), as well as clarify ketamine’s cellular actions that may cause it to function as a neurotoxic agent (resulting in adverse neuronal/glial health or cell death).
On the History of Ketamine
Ketamine was first synthesized in 1962 as a shorter acting analog of phencyclidine with less intense postoperative delirium (), and was approved for use in humans as an anesthetic in the United States by 1970 (; ). Ketamine began to be abused as a dissociative psychotomimetic in the late 1970s, primarily by soldiers in the Vietnam War (where it was widely used as a battle-field analgesic/anesthetic), and on the East Coast of the United States (). The Drug Enforcement Agency classifies ketamine as a Schedule III drug because of its low to moderate potential for dependence (). Ketamine’s anesthetic effects require infusions at a rate of ∼1 mg/kg/hr, and its low cost has made it useful for surgeries in low-resource settings, in pediatric age groups, and in those vulnerable to hypotension. It has also been applied as an adjunct treatment for chronic pain (∼0.1 mg/kg/hr), including for patients with opioid-induced hyperalgesia. The ability of subanesthetic ketamine (0.5 mg/kg over ∼40 min) to serve as a fast-acting antidepressant in treatment-resistant depression was demonstrated first in a clinical trial published in 2000 (; ). More widespread and routine clinical use has been limited by ketamine’s side effects and its abuse potential (). Nevertheless, its antidepressant properties have since been studied extensively, and more recent research suggests that the neuroprotective effects of subanesthetic dose ketamine infusions may provide a novel therapeutic avenue for acute neuronal injury, neurodegenerative disorders, and other neuropsychiatric disorders (; ).
On the Cell Membrane Pharmacology of Ketamine
Ketamine is a non-competitive antagonist of NMDARs. NMDARs are Ca2+-permeable ion channels that play critical roles in synaptic function, plasticity, learning, and memory as well as excitotoxicity and nervous system injury and disease (; ). NMDARs function as heterotetramers comprised of two obligatory GluN1 subunits in combination with two GluN2 (A-D) and/or GluN3 (A,B) subunits, each with distinct biophysical, pharmacological, and signaling properties (). NMDAR activation requires both the binding of the excitatory neurotransmitter glutamate (with co-agonist glycine or D-serine) and depolarization, which relieves a voltage-dependent magnesium (Mg2+) block to allow cation entry. Ketamine inhibits NMDARs at sub-micromolar concentrations, and its inhibitory actions are enhanced by Mg2+ in a subunit specific manner (). Stereoisomers and metabolites of ketamine [such as esketamine or (2S,6S)-hydroxynorketamine] also inhibit NMDARs to varying degrees. Multiple lines of evidence across a range of preclinical models indicate that NMDAR antagonism plays a central role in ketamine’s neuroprotective effects, particularly as it relates to glutamate-mediated excitotoxicity and downstream dysregulation of calcium homeostasis following status epilepticus (SE) or traumatic brain injury with administered doses ranging from 5 to 45 mg/kg (; ; ). For example, one study showed that ketamine (45 mg/kg) and midazolam (4.5 mg/kg) were equivalent in their ability to abort SE and reduce its long-term effects in adult rats (). Another study looking at neuroprotection against SE-induced brain damage during developmental periods demonstrated that blockade of GluN2B-containing NMDARs by CI-1041 (10 mg/kg) and ketamine (25 mg/kg) substantially reduced SE-induced neurodegeneration and microglial recruitment/activation (). The neuroprotective effects achieved by ketamine’s NMDA antagonism may extend to other conditions associated with a loss of blood-brain barrier integrity (such as depression, schizophrenia, and high grade glial tumors), negating the potentially deleterious excitotoxic effects of plasma-circulating glycine and glutamate (; ; ; ).
Insights into the neuroprotective features of ketamine may be extrapolated from a rich and recent rodent literature on the mechanisms of ketamine’s rapid antidepressant actions, which have been linked to increases in hippocampal neurogenesis (), enhanced synaptogenesis (), and synaptic connectivity (). NMDAR antagonism is central to ketamine’s therapeutic potential and extends to its antidepressant-like properties. demonstrated that a single ketamine injection (3 mg/kg) produced a rapid antidepressant effect on the forced swim test (FST) that was similar to (and more long lasting than) the NMDA antagonist MK-801 (0.1 mg/kg), reproducing earlier results by (2.5 mg/kg). Similarly, a selective blockade of GluN2B-containing NMDARs produced rapid antidepressant-like effects in rats ().
While NMDARs are broadly expressed in both excitatory and inhibitory neurons, the antidepressant-like effects of ketamine seem to require actions at inhibitory interneurons (iINs) (; ; ). As such, the “disinhibition hypothesis” posits that ketamine’s antagonism of NMDARs on GABAergic iINs causes the disinhibition of downstream excitatory pyramidal neurons (PNs), resulting in activity-dependent synaptic plasticity (that requires protein synthesis) and antidepressant-like or neuroprotective effects (; ; ; ). In support of this hypothesis, genetic deletions of GluN2B in iINs abolished the antidepressant effects of ketamine (). Similarly, at 10 mg/kg, ketamine’s inhibition of parvalbumin-positive iINs was found to be crucial for its ability to promote plasticity in the primary visual cortex using a model of monocular deprivation (). also demonstrated that ketamine and NMDAR antagonists with antidepressant effects function to reduce input from iINs, ultimately enhancing the excitability of excitatory PNs. While such disinhibition might be among the most immediate triggers of antidepressant cascades, other mechanisms, including direct NMDAR antagonism on PNs, are also likely involved ().
The “direct inhibition” hypothesis, also supported by a range of preclinical studies, suggests that the direct inhibition of PNs through NMDAR antagonism induces a rebound homeostatic synaptic plasticity (as opposed to excitation-induced activity-dependent synaptic plasticity), which in turn causes an enhanced excitatory synaptic drive onto these neurons (). For example, showed that genetic deletion of NMDARs from iINs does not prevent a GluN2B-specific antagonist from being able to elicit an antidepressant-like response in the medial prefrontal cortex (mPFC), as measured by the FST (). The two distinct cellular pathways described by the “disinhibition” and “direct inhibition” hypotheses may not be mutually exclusive, and the relative contributions of NMDARs in inhibitory and pyramidal neuron populations may vary by brain region and synapse types, as well developmental stage (). Furthermore, the role of NMDARs in ketamine’s mechanism of action more generally is unclear: reported that the metabolite (2R,6R)-hydroxynorketamine possesses similar antidepressant effects but with substantially lower NMDAR affinity, and instead involves and early and sustained activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPARs) (). While the NMDAR-independence of ketamine’s antidepressant actions remains an ongoing debate (; ; ), clinical evaluations of HNK levels have also been explored (): one study showed that higher levels of this ketamine metabolite in plasma are associated with less clinical improvement and suicidal thoughts ().
N-methyl-D-aspartate receptors are positioned both at synaptic compartments and extrasynaptic compartments. While the precise quantitative contribution of extrasynaptic NMDAR signaling (activated by excess ambient glutamate) has been classically difficult to measure (), extrasynaptic NMDARs are thought to constitute about 29–33% of the total NMDAR pool (at least in hippocampal dendrites) () with NMDAR subunit mobility within the membrane contributing to a shifting pool of synaptic and extrasynaptic NMDARs (). While synaptic NMDAR signaling plays a central role in activity-dependent plasticity and downstream transcriptional changes that ultimately mediate modifications in synapse strength, extrasynaptic NMDAR signaling is linked to the downstream excitotoxic effects secondary to glutamate spillover. The predominant working model regarding these distinct NMDAR subpopulations is that the activation of synaptic NMDARs initiates pro-survival pathways, whereas the activation of the extrasynaptic receptors activate pro-apoptotic pathways (). substantiate this model, showing that the cytotoxicity of repetitive ketamine exposure in the anterior cingulate cortex of neonatal rats was linked to heightened channel activity at GluN2B. Furthermore, several studies have found that selective antagonism of GluN2B, found more predominantly in extrasynaptic pools within adult model systems (), is sufficient to produce antidepressant-like effects, including increased levels of synaptic proteins (; ; ; ; ).
The association of synaptic receptors with neuroprotection and extrasynaptic receptors with neurotoxicity seems to shed some light on the question of how the same drug can have opposite effects at different doses. However, other experiments suggest that this understanding of the difference between NMDAR subtypes may be flawed. By measuring protein levels associated with pro-death (caspase-3) and pro-survival (phosphor [p]-CREB, p-AKT, p-ERK 1/2, BDNF) signaling pathways, found that NMDAR-mediated glutamate excitotoxicity in 14-day old rat primary cortical neurons was a function of the magnitude and duration of co-activation of both types of receptors. Such findings cast doubt on the hypothesis that synaptic and extrasynaptic NMDARs play oppositional roles (). further substantiated this co-activation hypothesis: extending upon the experiments done by they found that in acute brain slices of the adult rat frontal cortex, NMDAR co-activation led to an inhibition of pro-survival signaling pathways (decreased levels of p-CREB, p-ERK1/2, p-AKT) and cell death. Questions surrounding these alternative hypotheses are further complicated by the substantial differences in pharmacological properties of NMDARs between laboratory rodents and humans. Differences in subunit localization, composition and resultant patterns of NMDAR inhibition may influence downstream signaling cascades and the neuroprotective/neurotoxic balance of ketamine (; ).
More recent explorations of ketamine’s upstream membrane targets indicate that the full-fledged antidepressant actions of ketamine require AMPAR signaling. showed that (2R,6R)-HNK, which has a relatively low binding affinity for the NMDAR and does not act as an NMDAR antagonist, was nevertheless able to exert antidepressant-like effects. Blocking AMPARs with NBQX abolished ketamine’s antidepressant effects on the FST, tail-suspension test, and learned helplessness paradigm (; ; ; ). Another study concluded that AMPAR activation was necessary for ketamine’s activation of the mammalian target of rapamycin (mTOR) pathway, and subsequent upregulation of synaptic signaling proteins and dendritic spine formation (). also showed that the antidepressant effects of ketamine (0.5, 2.5, 10 mg/kg), Ro 25-6981 (1, 3, 10 mg/kg), and MK-801 (0.05, 0.1, 0.2 mg/kg) all required AMPAR activation, and that the combination of AMPAR potentiating agents with even lower doses of NMDAR antagonists might be useful for the treatment of depression.
Studies examining the involvement of AMPAR activation in ketamine’s mechanism of action have largely focused on the antidepressant effects of ketamine; a role for AMPAR signaling in broader forms of neuroprotection has not been addressed with as much vigor. Several other membrane receptors have also been demonstrated to bind ketamine, including sigma-1 receptors, nicotinic acetylcholine receptors, voltage gated calcium channels, and HCN channels (). In addition, identified a novel mechanism by which ketamine might exert its neuroprotective effect. Using an immortalized C6 glioma cell line, this group showed that ketamine induced a translocation of Gαs from lipid raft to non-raft domains, resulting in an increase in intracellular cAMP and a subsequent phosphorylation and activation of transcriptional regulator CREB, ultimately upregulating production of brain-derived neurotrophic factor (BDNF). This effect was present after subunit GluN1 knockdown, demonstrating the possibility of yet another NMDAR-independent mechanism of ketamine (). While GluN3/GluN2 subunits display a substantial reduction in glutamate or glycine-activated currents, the actions of ketamine on GluN1 lacking NMDARs remains poorly defined ().
Ketamine as a Regulator of BDNF Signaling
Reductions in the expression or release of BDNF, which act on tropomyosin-related kinase B (TrkB) receptors, have been implicated as both a mediator and modulator of neuronal degeneration, and as an important cellular biomarker of the depressed state (; ). Two major arms of intracellular signaling responses to subanesthetic ketamine have been explored, both of which ultimately culminate in the upregulation of BDNF. The first signaling pathway emphasizes ketamine’s activation of the mTOR pathway. BDNF release activates TrkB receptors and downstream signaling pathways which in turn upregulate synaptic signaling proteins and dendritic spine formation in brain regions such as the prefrontal cortex (). Blockade of mTOR signaling abolished ketamine-induced synaptogenesis and the corresponding antidepressant-like behavioral responses (). Another study showed that subanesthetic ketamine (20 mg/kg) attenuates the development of levodopa-induced dyskinesia (LID) and in a 6-hydroxydopa model of parkinsonism. This long-term anti-dyskinetic effect was associated with BDNF release in the striatum and subsequent activation of ERK1/2 and mTOR pathway signaling, and the behavioral effects correlated more with changes in synaptic morphology (). Although significant basic science literature suggests that ketamine’s effects are mediated by mTOR activation, a recent clinical study found that blocking mTOR with rapamycin prior to administering ketamine did not alter the antidepressant effects of ketamine after 24 h and actually prolonged the antidepressant effects after 2 weeks (). These unexpected results reflect challenges in translating the preclinical findings regarding ketamine’s modulation of mTOR to a clinical setting.
Likely nodes in intracellular signaling downstream of TrkB connecting ketamine to mTOR activation include PI3K, AKT, and GSK-3 (which is inactivated by PI3K-AKT signaling). In a rat model of combined amyloid-beta and isoflurane-induced cognitive impairment, ketamine (2.5, 5, or 10 mg/kg) rescued spatial memory deficits on the Morris Water Maze paradigm and promoted BDNF production through upregulation of the PI3K/AKT/GSK-3β pathway. Ketamine-treated rats also displayed a dose-dependent reduction in Aβ peptide accumulation (). Another study employing GSK-3α21A/21A/β9A/9A knockin mice, which express constitutively active GSK-3 isoforms that are resistant to ketamine inhibition, demonstrated that GSK-3 inactivation is necessary for ketamine-induced upregulation of AMPAR GluA1 subunits associated with ketamine’s antidepressant effects (). In contrast, showed that ketamine’s ability to offer cytoprotective effects against cortisone-induced cell death occur via the activation of Akt/mTOR/S6 kinase signaling without inactivating GSK-3. propose a separate potential mechanism for mTOR activation and neuroprotection, in which ketamine mediates the NO/GAPDH/Siah1 NMDAR-dependent pathway. Normally, NMDAR activation leads to the degradation of the small GTPase Rheb, which prevents mTOR activation. By blocking NMDAR activation, ketamine stabilizes Rheb, which in turn increases mTOR activation ().
The second intracellular pathway implicated in inducing BDNF upregulation in response to subanesthetic ketamine treatment involves the eukaryotic elongation factor 2 kinase (eEF2K) as responsible for BDNF upregulation (). focused on eEF2K rather than mTOR and found that ketamine’s fast-acting and sustained antidepressant responses required AMPAR activation and BDNF translation through the deactivation of eEF2K. In line with these findings, one study demonstrated that memantine’s inability to inhibit the phosphorylation of eEFK2 precluded it from upregulating BDNF expression and imparting an antidepressant effect (). The antidepressant effects of (2R-6R)-HNK (10 mg/kg intraperitoneally or 50 μM bath application) also include eEF2 inactivation (; ) and mice with deletions of eEF2K do not display ketamine-induced antidepressant effects ().
Ketamine-induced increases in BDNF may promote synaptogenesis: one study examined the effects of genetically impaired BDNF mRNA trafficking in mouse mPFC pyramidal neurons and found that ketamine-induced synaptogenesis is dependent on the dendritic translation and release of BDNF (). Even (2R-6R)-HNK, a ketamine metabolite with a significantly lower NMDAR affinity, requires BDNF and TrkB activation for its antidepressant effects (). Finally, showed that 3.0 mg/kg ketamine administered to mice with a conditional Bdnf-knockout failed to produce antidepressant-like effects. These findings suggest that the mTOR/BDNF pathway, possibly through an NMDAR-independent mechanism, is critical for the antidepressant-like effects of ketamine ().
Downstream Effects of Ketamine: Inflammatory Signaling, Antioxidant Stress, Autophagy, and Apoptosis
Given ketamine’s popular use as an anesthetic for pediatric patient populations (; ; ), the vast majority of studies that have explored ketamine’s potential neurotoxic effects have applied ketamine within developmental critical windows. Ketamine is known to have neurotoxic effects at high doses especially in models of developing neurons (; ; ; ), which display greater and longer NMDAR blockade when compared to mature neurons (; ) and have relatively lower quantities of GluN2A (; ). Ketamine and other NMDAR antagonists have also been described to result in cytoplasmic vacuolization in cingulate and retrosplenial neurons (“Olney’s lesions”) at doses of 40 mg/kg, but not at 5, 10, and 20 mg/kg (). A more contemporary neuropathological evaluation compared single and multiple doses of ketamine (up to 60 mg/kg) and MK801 and 2R-6R-HNK: only rats treated with single or multiple doses of MK-801 developed evidence of Olney’s lesions ().
Ketamine’s ability to promote either cell survival or cell death depending on its dose was aptly illustrated by a study which found that subanesthetic ketamine (5 mg/kg) prevented widespread apoptosis caused by more anesthetic doses (20 mg/kg) via the upregulation of Activity-Dependent Neuroprotective Protein (ADNP) (). This finding may have enormous clinical relevance, given ketamine’s popularity as an anesthetic in pediatric age groups. A review by argues that even at anesthetic doses, ketamine can have neurotoxic and/or neuroprotective effects on developing brains, depending on dose, timing, frequency, and the presence or absence of noxious stimuli. Anesthetic ketamine may exert neurotoxic effects through NMDAR blockade and subsequent compensatory NMDAR upregulation, while also serving a neuroprotective role by inhibiting inflammation-mediated toxicity associated with surgery and promoting synaptic plasticity through the release of BDNF in the hippocampus (). A significant number of preclinical studies have explored the mechanisms underlying ketamine-induced neurotoxicity in search for therapeutic agents that might protect developing neurons against the neurotoxicity of ketamine (; ; ). Preclinical findings, however, are not always obviously observable clinically, and long-term neurocognitive safety assessments following anesthetic ketamine exposure in pediatric age groups have not consistently identified clinically meaningful correlates of neurotoxicity ().
The neurotoxic properties of ketamine on developing neurons may be ameliorated by harnessing the very same pathways implicated in ketamine’s neuroprotective effects. For example, one study showed that siRNA mediated inhibition of GSK-3β can prevent ketamine-induced toxicity in neural stem cell-derived neurons (), and another showed that the antioxidant edaravone can protect cultured primary rat cortical neurons from ketamine-induced apoptosis through activation of the PI3K/Akt signal pathway and by reducing oxidative phosphorylation (). Additionally, several studies have linked ketamine-induced neurotoxicity to high levels of reactive oxygen species (ROS)/malondialdehyde (MDA) generation, reduced total antioxidant capacity, and subsequently to high levels of autophagy- and apoptosis-related proteins (; ; ). However, a recent study showed that in a zebrafish model, ketamine had a protective effect and actually reduced levels of ROS in vivo in a concentration-dependent manner ().
Even at the cellular level, ketamine’s effects at different dosages can be directly oppositional. The literature on ketamine’s neuroprotective potential emphasizes the increased expression of BDNF as crucial to promoting synaptogenesis, cell survival, and in vivo, improvement in terms of a variety of behavioral measures. However, one recent study showed that prolonged exposure of postnatal day 7 (P7) rat pups to ketamine (20 mg/kg per dose) decreased BDNF expression and the phosphorylation of AKT and ERK and increased apoptosis in the developing rat hippocampus, which corresponded with later cognitive impairments ().
Ketamine’s activation of mTOR appears to play a central role in its neuroprotective and antidepressant-like effects, yet some studies show that mTOR activation can have differential effects on cell health (; ; ). For example, showed that subanesthetic ketamine injections (8 mg/kg) produced neuroprotective effects in a mouse model of Parkinson disease (PD), which corresponded with elevated expression of autophagy markers and reduced mTOR activation compared to untreated PD mice. These results suggest that subanesthetic ketamine may support motor and cognitive function in PD by actually enhancing autophagy, degrading abnormally aggregated proteins and thereby preventing neuronal apoptosis (). showed that ketamine treatment of cultured rat hippocampal neurons induced a dose-dependent increases in apoptosis that was associated with a dose-dependent activation of the mTOR pathway. Inhibition of mTOR signaling by rapamycin protected rat hippocampal neurons from ketamine-induced injuries by reducing apoptosis, oxidative stress, and Ca2+ concentration (), and co-administered rapamycin blocks ketamine’s antidepressant effects (). Notably, used immature fetal hippocampal neurons in their study, so their results may have been impacted by known differences in the predominance and localization of GluN2A and GluN2B-containing NMDARs in developing brains as compared to adult brains (). Lastly, in attempting to assess the ability of pituitary adenylate cyclase-activating polypeptide (PACAP) to shield adult neural stem cells from the neurotoxic effects of anesthetic ketamine (50 μM, 200 μM, 400 μM, and 1 mM s-ketamine medium), also showed that ketamine’s activation of AMPA receptors leads to mTOR activation in vitro, which, rather than promoting neuroprotection, contributed to ER stress and apoptosis.
Ketamine’s ability to exert contradictory effects extends to proteins involved in inflammation and autophagy. In evaluating ketamine’s effectiveness as a neuroprotectant in rat hippocampal tissue in a model of TBI, demonstrated that at 10 mg/kg every 24 h up to 7 days, ketamine attenuates neuroinflammation by inhibiting production of IL-6 and TNF-α and downregulates autophagy by activating the mTOR pathway. One study showed that in human lymphocytes, NMDAR activation resulted in ROS production and upregulation of NMDAR expression. MK-801, a non-competitive NMDAR antagonist, mitigated this process, suggesting that the anti-inflammatory effects of ketamine might also be mediated in part by ketamine’s regulation of non-neuronal cells (). Another study found that IL-6, IL-8, and IL-1β production increased in the hippocampus after 80 mg/kg intravenous ketamine administration regardless of frequency and duration (). This study also found that TNF-α expression increased after a single administration of 80 mg/kg ketamine but decreased significantly after multiple and long-term administration (20, 40, and 80 mg/kg, 6 doses at 1 h intervals) (; ).
Discussion
Although there has been a substantial increase in preclinical research regarding ketamine’s neuroprotective potential over the past two decades, uncertainty persists at each mechanistic step. At the cell membrane, ketamine clearly functions as an NMDA antagonist, but whether this is required for all forms of ketamine’s ultimate neuroprotective actions is less clear. AMPAR activation, whether a response to NMDAR blockade or to some other cellular effects of ketamine, appears to play an important functional role in ketamine’s antidepressant mechanisms. Ketamine’s upregulation of BDNF, crucial for synaptogenesis and adaptive plasticity mechanisms, may occur through mTOR pathway activation, inhibition of eEF2K phosphorylation, or both. A wealth of preclinical evidence also clarifies the neurotoxic effects of ketamine, with endpoints that include increased oxidative stress autophagy and apoptosis. This apparent contradiction can likely be explained by the dose of ketamine used or by molecular differences between developing and adult brains, such as the number, strength, and composition of NMDAR-containing synapses and increases in synaptic contacts that occur during development ().
A comprehensive understanding of ketamine’s effects on intracellular signaling remains a work in progress. Even within the realm of rapid antidepressant effects, there remain controversies about NMDAR independence and the cellular sites of action (PNs vs. INs). Currently, the basic science literature on ketamine paints a mixed picture as ketamine is studied in the context of a variety of disease models, cell types, brain regions, and employing a range of administration protocols (dose, frequency, route, etc.). It is therefore necessary to undertake more systematic studies of ketamine’s long-term safety that incorporate a multidisciplinary approach to incorporate measures of wellbeing, including cell death and protein (such as BDNF) levels for in vitro studies, and in vivo behavioral assessments that go beyond the forced swim test. Since ketamine is used broadly in veterinary research and medicine, non-rodent animal subjects are also viable models for study and could be used to help bridge the gap between basic science and clinical research. In addition, some standardization among cell-culture based models would allow us to obtain a more unified perspective on ketamine’s actions. Rather than focusing solely on particular nodes in the proposed mechanistic pathways, “omics”-based approaches may offer a more unbiased appreciation of the spectrum of ketamine’s cellular effects. Finally, it will be important to continue to develop and investigate analogs of ketamine that might serve as alternatives with decreased neurotoxic potential and reduced psychotomimetic effects.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
DC wrote the first draft of the manuscript. All authors contributed to manuscript revision and approved the submitted version.
Funding
VK receives seed funding from the Baylor College of Medicine’s Office of Research. AA was supported by NICHD R00HD085188 and KT was supported by NIH Grants R01NS062829 and R01MH109511.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbdallahC. G.AverillL. A.GueorguievaR.GoktasS.PurohitP.RanganathanM.et al (2020). Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.Neuropsychopharmacology45990–997. 10.1038/s41386-020-0644-9
2
AbdallahC. G.SanacoraG.DumanR. S.KrystalJ. H. (2018). The neurobiology of depression, ketamine and rapid-acting antidepressants: is it glutamate inhibition or activation?Pharmacol. Ther.190148–158. 10.1016/j.pharmthera.2018.05.010
3
AutryA. E.AdachiM.NosyrevaE.NaE. S.LosM. F.ChengP. F.et al (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.Nature47591–96. 10.1038/nature10130
4
BaiX.YanY.CanfieldS.MuravyevaM. Y.KikuchiC.ZajaI.et al (2013). Ketamine enhances human neural stem cell proliferation and induces neuronal apoptosis via reactive oxygen species-mediated mitochondrial pathway.Anesth. Analg.116869–880. 10.1213/ANE.0b013e3182860fc9
5
BartlettM. J.FloresA. J.YeT.SmidtS. I.DollishH. K.StancatiJ. A.et al (2020). Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.Exp. Neurol.333:113413. 10.1016/j.expneurol.2020.113413
6
BawariS.TewariD.ArgüellesS.SahA. N.NabaviS. F.XuS.et al (2019). Targeting BDNF signaling by natural products: novel synaptic repair therapeutics for neurodegeneration and behavior disorders.Pharmacol. Res.148:104458. 10.1016/j.phrs.2019.104458
7
BellJ. D. (2017). In vogue: ketamine for neuroprotection in acute neurologic injury.Anesth. Analg.1241237–1243. 10.1213/ANE.0000000000001856
8
BermanR. M.CappielloA.AnandA.OrenD. A.HeningerG. R.CharneyD. S.et al (2000). Antidepressant effects of ketamine in depressed patients.Biol. Psychiatry47351–354. 10.1016/S0006-3223(99)00230-9
9
BeurelE.GriecoS. F.AmadeiC.DowneyK.JopeR. S. (2016). Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.Bipolar Disord.18473–480. 10.1111/bdi.12436
10
BrownB. P.KangS. C.GawelekK.ZachariasR. A.AndersonS. R.TurnerC. P.et al (2015). In vivo and in vitro ketamine exposure exhibits a dose-dependent induction of activity-dependent neuroprotective protein in rat neurons.Neuroscience29031–40. 10.1016/j.neuroscience.2014.12.076
11
ChenB. S.RocheK. W. (2007). Regulation of NMDA receptors by phosphorylation.Neuropharmacology53362–368. 10.1016/j.neuropharm.2007.05.018
12
ChenZ.ZhouQ.ZhangM.WangH.YunW.ZhouX. (2014). Co-activation of synaptic and extrasynaptic NMDA receptors by neuronal insults determines cell death in acute brain slice.Neurochem. Int.7828–34. 10.1016/j.neuint.2014.08.003
13
CollingridgeG. L.LeeY.BortolottoZ. A.KangH.LodgeD. (2017). Antidepressant actions of ketamine versus hydroxynorketamine.Biol. Psychiatry81e65–e67. 10.1016/j.biopsych.2016.06.029
14
Cull-CandyS.BrickleyS.FarrantM. (2001). NMDA receptor subunits: diversity, development and disease.Curr. Opin. Neurobiol.11327–335. 10.1016/S0959-4388(00)00215-4
15
DalyE. J.TrivediM. H.JanikA.LiH.ZhangY.LiX.et al (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial.JAMA Psychiatry76893–903. 10.1001/jamapsychiatry.2019.1189
16
DeyamaS.DumanR. S. (2020). Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine.Pharmacol. Biochem. Behav.188:172837. 10.1016/j.pbb.2019.172837
17
DongC.AnandK. J. S. (2013). Developmental neurotoxicity of ketamine in pediatric clinical use.Toxicol. Lett.22053–60. 10.1016/j.toxlet.2013.03.030
18
DudekK. A.Dion-AlbertL.LebelM.LeClairK.LabrecqueS.TuckE.et al (2020). Molecular adaptations of the blood–brain barrier promote stress resilience vs. Depression.Proc. Natl. Acad. Sci. U.S.A.1173326–3336. 10.1073/pnas.1914655117
19
DumanR. S.AghajanianG. K.SanacoraG.KrystalJ. H. (2016). Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.Nat. Med.22238–249. 10.1038/nm.4050
20
FanJ. C.SongJ. J.WangY.ChenY.HongD. X. (2017). Neuron-protective effect of subanesthestic-dosage ketamine on mice of Parkinson’s disease.Asian Pac. J. Trop. Med.101007–1010. 10.1016/j.apjtm.2017.09.014
21
FujikawaD. G. (2019). Starting ketamine for neuroprotection earlier than its current use as an anesthetic/antiepileptic drug late in refractory status epilepticus.Epilepsia60373–380. 10.1111/epi.14676
22
FukumotoK.FogacaM. V.LiuR. J.DumanC.KatoT.LiX. Y.et al (2019). Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine.Proc. Natl. Acad. Sci. U.S.A.116297–302. 10.1073/pnas.1814709116
23
GerhardD. M.PothulaS.LiuR. J.WuM.LiX. Y.GirgentiM. J.et al (2020). GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions.J. Clin. Investig.1301336–1349. 10.1172/JCI130808
24
GideonsE. S.KavalaliE. T.MonteggiaL. M. (2014). Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses.Proc. Natl. Acad. Sci. U.S.A.1118649–8654. 10.1073/pnas.1323920111
25
GriecoS. F.QiaoX.ZhengX.LiuY.ChenL.ZhangH.et al (2020). Subanesthetic ketamine reactivates adult cortical plasticity to restore vision from amblyopia.Curr. Biol.303591–3603.e8. 10.1016/j.cub.2020.07.008
26
GrunebaumM. F.GalfalvyH. C.ChooT. H.ParrisM. S.BurkeA. K.SuckowR. F.et al (2019). Ketamine metabolite pilot study in a suicidal depression trial.J. Psychiatr. Res.117129–134. 10.1016/j.jpsychires.2019.08.005
27
HardinghamG. E.BadingH. (2010). Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders.Nat. Rev. Neurosci.11682–696. 10.1038/nrn2911
28
HarrazM. M.TyagiR.CortésP.SnyderS. H. (2016). Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation.Mol. Psychiatry21313–319. 10.1038/mp.2015.211
29
HedegaardM.HansenK. B.AndersenK. T.Bräuner-OsborneH.TraynelisS. F. (2012). Molecular pharmacology of human NMDA receptors.Neurochem. Int.61601–609. 10.1016/j.neuint.2011.11.016
30
HighlandJ. N.ZanosP.RiggsL. M.GeorgiouP.ClarkS. M.MorrisP. J.et al (2021). Hydroxynorketamines: pharmacology and potential therapeutic applications.Pharmacol. Rev.73763–791. 10.1124/pharmrev.120.000149
31
HudetzJ. A.PagelP. S. (2010). Neuroprotection by ketamine: a review of the experimental and clinical evidence.J. Cardiothorac. Vasc. Anesth.24131–142. 10.1053/j.jvca.2009.05.008
32
JelenL. A.YoungA. H.StoneJ. M. (2021). Ketamine: a tale of two enantiomers.J. Psychopharmacol.2109–123. 10.1177/0269881120959644
33
JinJ.GongK.ZouX.WangR.LinQ.ChenJ. (2013). The blockade of NMDA receptor ion channels by ketamine is enhanced in developing rat cortical neurons.Neurosci. Lett.53911–15. 10.1016/j.neulet.2013.01.034
34
KangH.ParkP.BortolottoZ. A.BrandtS. D.ColestockT.WallachJ.et al (2017). Ephenidine: a new psychoactive agent with ketamine-like NMDA receptor antagonist properties.Neuropharmacology112144–149. 10.1016/j.neuropharm.2016.08.004
35
KimJ.FarchioneT.PotterA.ChenQ.TempleR. (2019). Esketamine for treatment-resistant depression — first FDA-approved antidepressant in a new class.N. Engl. J. Med.3811–4. 10.1056/nejmp1903305
36
KiselycznykC.JuryN. J.HalladayL. R.NakazawaK.MishinaM.SprengelR.et al (2015). NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism.Behav. Brain Res.28789–95. 10.1016/j.bbr.2015.03.023
37
KokaneS. S.GongK.JinJ.LinQ. (2017). Prolonged ketamine exposure induces increased activity of the GluN2B-containing N-methyl-D-aspartate receptor in the anterior cingulate cortex of neonatal rats.Neurotoxicol. Teratol.631–8. 10.1016/j.ntt.2017.07.005
38
KotermanskiS. E.JohnsonJ. W. (2009). Mg 2+ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine.J. Neurosci.292774–2779. 10.1523/JNEUROSCI.3703-08.2009
39
KrishnanV.NestlerE. J. (2008). The molecular neurobiology of depression.Nature455894–902. 10.1038/nature07455
40
KurdiM.TheerthK.DevaR. (2014). Ketamine: current applications in anesthesia, pain, and critical care.Anesth. Essays Res.8283–290. 10.4103/0259-1162.143110
41
LavenderE.Hirasawa-FujitaM.DominoE. F. (2020). Ketamine’s dose related multiple mechanisms of actions: dissociative anesthetic to rapid antidepressant.Behav. Brain Res.390:112631. 10.1016/j.bbr.2020.112631
42
LepackA. E.FuchikamiM.DwyerJ. M.BanasrM.DumanR. S. (2015). BDNF release is required for the behavioral actions of ketamine.Int. J. Neuropsychopharmacol.18:pyu033. 10.1093/ijnp/pyu033
43
LiL.VlisidesP. E. (2016). Ketamine: 50 years of modulating the mind.Front. Hum. Neurosci.10:612. 10.3389/fnhum.2016.00612
44
LiN.LeeB.LiuR. J.BanasrM.DwyerJ. M.IwataM.et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.Science329959–964. 10.1126/science.1190287
45
LiS. X.HanY.XuL. Z.YuanK.ZhangR. X.SunC. Y.et al (2018). Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects.Mol. Psychiatry23597–608. 10.1038/mp.2017.85
46
LiX.LiY.ZhaoJ.LiL.WangY.ZhangY.et al (2018). Administration of ketamine causes autophagy and apoptosis in the rat fetal hippocampus and in PC12 cells.Front. Cell. Neurosci.12:21. 10.3389/fncel.2018.00021
47
LiY.LiX.ZhaoJ.LiL.WangY.ZhangY.et al (2018). Midazolam attenuates autophagy and apoptosis caused by ketamine by decreasing reactive oxygen species in the hippocampus of fetal rats.Neuroscience388460–471. 10.1016/j.neuroscience.2018.03.040
48
LiY.ShenR.WenG.DingR.DuA.ZhouJ.et al (2017). Effects of ketamine on levels of inflammatory cytokines IL-6, IL-1β, and TNF-α in the hippocampus of mice following acute or chronic administration.Front. Pharmacol.8:139. 10.3389/fphar.2017.00139
49
LiuF. F.ZhaoS.LiuP.HuoS. P. (2019). Influence of mTOR signaling pathway on ketamine-induced injuries in the hippocampal neurons of rats.Neurol. Res.4177–86. 10.1080/01616412.2018.1531203
50
LiuR. J.LeeF. S.LiX. Y.BambicoF.DumanR. S.AghajanianG. K. (2012). Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.Biol. Psychiatry71996–1005. 10.1016/j.biopsych.2011.09.030
51
LopezM. J.TadiP. (2020). “Drug enforcement administration drug scheduling,” in StatPearls, ed.AbaiB. (Treasure Island, FL: StatPearls Publishing). Available online at: https://www.ncbi.nlm.nih.gov/books/NBK431128/
52
LossC. M.da RosaN. S.MestrinerR. G.XavierL. L.OliveiraD. L. (2019). Blockade of GluN2B-containing NMDA receptors reduces short-term brain damage induced by early-life status epilepticus.NeuroToxicology71138–149. 10.1016/j.neuro.2019.01.002
53
MadeiraC.AlheiraF. V.CalciaM. A.SilvaT. C. S.TannosF. M.Vargas-LopesC.et al (2018). Blood levels of glutamate and glutamine in recent onset and chronic schizophrenia.Front. Psychiatry9:713. 10.3389/fpsyt.2018.00713
54
MaengS.ZarateC. A.DuJ.SchloesserR. J.McCammonJ.ChenG.et al (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-propionic acid receptors.Biol. Psychiatry63349–352. 10.1016/j.biopsych.2007.05.028
55
MansouriS.AgartzI.ÖgrenS.-O.PatroneC.LundbergM. (2017). PACAP protects adult neural stem cells from the neurotoxic effect of ketamine associated with decreased apoptosis, ER stress and mTOR pathway activation.PLoS One12:e0170496. 10.1371/journal.pone.0170496
56
MashkinaA. P.TyulinaO. V.SolovyovaT. I.KovalenkoE. I.KanevskiL. M.JohnsonP.et al (2007). The excitotoxic effect of NMDA on human lymphocyte immune function.Neurochem. Int.51356–360. 10.1016/j.neuint.2007.04.009
57
McCannM. E.SorianoS. G. (2019). Does general anesthesia affect neurodevelopment in infants and children?BMJ367l6459. 10.1136/bmj.l6459
58
MengC.YaoX. Q.ChangR. J.WangS. L.WangX.MaD. Q.et al (2020). Exogenous GM1 ganglioside attenuates ketamine-induced neurocognitive impairment in the developing rat brain.Anesth. Analg.130505–517. 10.1213/ANE.0000000000004570
59
MillerO. H.MoranJ. T.HallB. J.BaselC.HoffmannF. (2015). Two cellular hypotheses explaining the initiation of ketamine’s antidepressant actions: direct inhibition and disinhibition.Neuropharmacology10017–26. 10.1016/j.neuropharm.2015.07.028
60
MillerO. H.YangL.WangC. C.HargroderE. A.ZhangY.DelpireE.et al (2014). GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine.ELife3:e03581. 10.7554/eLife.03581
61
MionG. (2017). History of anaesthesia.Eur. J. Anaesthesiol.34571–575. 10.1097/EJA.0000000000000638
62
MoldavskiA.BehrJ.BadingH.BengtsonC. P. (2020). A novel method using ambient glutamate for the electrophysiological quantification of extrasynaptic NMDA receptor function in acute brain slices.J. Physiol.598633–650. 10.1113/JP278362
63
MonteggiaL. M.GideonsE.KavalaliE. T. (2013). The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine.Biol. Psychiatry731199–1203. 10.1016/j.biopsych.2012.09.006
64
MorrisP. J.BurkeR. D.SharmaA. K.LynchD. C.Lemke-BoutcherL. E.MathewS.et al (2021). A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801.Neurotoxicol. Teratol.87:106993. 10.1016/j.ntt.2021.106993
65
NiquetJ.BaldwinR.NormanK.SuchomelovaL.LumleyL.WaterlainC. G. (2017). Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces morris water maze deficits.Physiol. Behav.176139–148. 10.1111/epi.13480.Midazolam-Ketamine
66
NosyrevaE.AutryA. E.KavalaliE. T.MonteggiaL. M. (2014). Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade.Front. Mol. Neurosci.7:94. 10.3389/fnmol.2014.00094
67
NosyrevaE.SzablaK.AutryA. E.RyazanovA. G.MonteggiaL. M.KavalaliE. T. (2013). Acute suppression of spontaneous neurotransmission drives synaptic potentiation.J. Neurosci.336990–7002. 10.1523/JNEUROSCI.4998-12.2013
68
OlneyJ. W.LabruyereJ.PriceM. T. (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs.Science2441360–1362. 10.1126/science.2660263
69
PaolettiP.BelloneC.ZhouQ. (2013). NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease.Nat. Rev. Neurosci.14383–400. 10.1038/nrn3504
70
ParsonsM. P.RaymondL. A. (2014). Extrasynaptic NMDA receptor involvement in central nervous system disorders.Neuron82279–293. 10.1016/j.neuron.2014.03.030
71
PribishA.WoodN.KalavaA. (2020). A Review of nonanesthetic uses of ketamine.Anesthesiol. Res. Pract.2020:5798285. 10.1155/2020/5798285
72
RobinsonB.GuQ.AliS. F.DumasM.KanungoJ. (2019). Ketamine-induced attenuation of reactive oxygen species in zebrafish is prevented by acetyl L-carnitine in vivo.Neurosci. Lett.70636–42. 10.1016/j.neulet.2019.05.009
73
SaijaA.PrinciP.De PasqualeR.CostaG. (1989). Modifications of the permeability of the blood-brain barrier and local cerebral metabolism in pentobarbital- and ketamine-anaesthetized rats.Neuropharmacology28997–1002. 10.1016/0028-3908(89)90202-5
74
SanacoraG.FryeM. A.McDonaldW.MathewS. J.TurnerM. S.SchatzbergA. F.et al (2017). A consensus statement on the use of ketamine in the treatment of mood disorders.JAMA Psychiatry74399–405. 10.1001/jamapsychiatry.2017.0080
75
SmothersC. T.WoodwardJ. J. (2007). Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits.J. Pharmacol. Exp. Ther.322739–748. 10.1124/jpet.107.123836
76
SorianoS. G.LiuQ.LiJ.LiuJ. R.HanX. H.KanterJ. L.et al (2010). Ketamine activates cell cycle signaling and apoptosis in the neonatal rat brain.Anesthesiology1121155–1163. 10.1097/ALN.0b013e3181d3e0c2
77
SumiyoshiT.AnilA. E.JinD.JayathilakeK.LeeM.MeltzerH. Y. (2004). Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms.Int. J. Neuropsychopharmacol.71–8. 10.1017/S1461145703003900
78
SuzukiK.NosyrevaE.HuntK. W.KavalaliE. T.MonteggiaL. M. (2017). Effects of a ketamine metabolite on synaptic NMDAR function.Nature546E1–E3. 10.1038/nature22084
79
SzczurowskaE.MaresP. (2013). NMDA and AMPA receptors: development and status epilepticus.Physiol. Res.62(Suppl. 1), S21–S38. 10.33549/PHYSIOLRES.932662
80
TavaresM. K.dos ReisS.PlattN.HeinrichI. A.WolinI. A. V.LealR. B.et al (2018). Agmatine potentiates neuroprotective effects of subthreshold concentrations of ketamine via mTOR/S6 kinase signaling pathway.Neurochem. Int.118275–285. 10.1016/j.neuint.2018.05.006
81
TovarK. R.WestbrookG. L. (2002). Mobile NMDA receptors at hippocampal synapses.Neuron34255–264. 10.1016/S0896-6273(02)00658-X
82
WangC. Q.YeY.ChenF.HanW. C.SunJ. M.LuX.et al (2017). Posttraumatic administration of a sub-anesthetic dose of ketamine exerts neuroprotection via attenuating inflammation and autophagy.Neuroscience34330–38. 10.1016/j.neuroscience.2016.11.029
83
WangQ.ShenF. Y.ZouR.ZhengJ. J.YuX.WangY. W. (2017). Ketamine-induced apoptosis in the mouse cerebral cortex follows similar characteristic of physiological apoptosis and can be regulated by neuronal activity.Mol. Brain10:24. 10.1186/s13041-017-0302-2
84
WangR.ZhangZ.KumarM.XuG.ZhangM. (2019). Neuroprotective potential of ketamine prevents developing brain structure impairment and alteration of neurocognitive function induced via isoflurane through the PI3K/AKT/GSK-3β pathway.Drug Des. Dev. Therapy13501–512. 10.2147/DDDT.S188636
85
WidmanA. J.McMahonL. L. (2018). Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy.Proc. Natl. Acad. Sci. U.S.A.115E3007–E3016. 10.1073/pnas.1718883115
86
WrayN. H.SchappiJ. M.SinghH.SeneseN. B.RasenickM. M. (2019). NMDAR-independent, cAMP-dependent antidepressant actions of ketamine.Mol. Psychiatry241833–1843. 10.1038/s41380-018-0083-8
87
XiaP.ChenH. S. V.ZhangD.LiptonS. A. (2010). Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses.J. Neurosci.3011246–11250. 10.1523/JNEUROSCI.2488-10.2010
88
YamadaJ.JinnoS. (2019). Potential link between antidepressant-like effects of ketamine and promotion of adult neurogenesis in the ventral hippocampus of mice.Neuropharmacology158:107710. 10.1016/j.neuropharm.2019.107710
89
YanJ.JiangH. (2014). Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain.J. Neurosurg. Anesthesiol.26155–160. 10.1097/ANA.0000000000000027
90
YangB.RenQ.MaM.ChenQ. X.HashimotoK. (2016). Antidepressant effects of (+)-MK-801 and (−)-MK-801 in the social defeat stress model.Int. J. Neuropsychopharmacol.19:pyw080. 10.1093/ijnp/pyw080
91
YoungC.Jevtovic-TodorovicV.QinY. Q.TenkovaT.WangH.LabruyereJ.et al (2005). Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain.Br. J. Pharmacol.146189–197. 10.1038/sj.bjp.0706301
92
ZanosP.MoaddelR.MorrisP. J.GeorgiouP.FischellJ.ElmerG. I.et al (2017). Zanos et al. reply.Nature546E4–E5. 10.1038/nature22085
93
ZanosP.MoaddelR.MorrisP. J.GeorgiouP.FischellJ.ElmerG. I.et al (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites.Nature533481–486. 10.1038/nature17998
94
ZhangJ.CuiC.LiY.XuH. (2018). Inhibition of GSK-3beta signaling pathway rescues ketamine-induced neurotoxicity in neural stem cell-derived neurons.Neuromolecular Med.2054–62. 10.1007/s12017-017-8472-8
95
ZhouQ.ShengM. (2013). NMDA receptors in nervous system diseases.Neuropharmacology7469–75. 10.1016/j.neuropharm.2013.03.030
96
ZhouX.HollernD.LiaoJ.AndrechekE.WangH. (2013). NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors.Cell Death Dis.4:e560. 10.1038/cddis.2013.82
97
ZuoD.LinL.LiuY.WangC.XuJ.SunF.et al (2016). Baicalin attenuates ketamine-induced neurotoxicity in the developing rats: involvement of PI3K/Akt and CREB/BDNF/Bcl-2 pathways.Neurotox. Res.30159–172. 10.1007/s12640-016-9611-y
Summary
Keywords
ketamine mechanism, neuroprotection, ketamine-induced neurotoxicity, BDNF, NMDA receptor, AMPA receptor, antidepressant
Citation
Choudhury D, Autry AE, Tolias KF and Krishnan V (2021) Ketamine: Neuroprotective or Neurotoxic?. Front. Neurosci. 15:672526. doi: 10.3389/fnins.2021.672526
Received
26 February 2021
Accepted
12 July 2021
Published
10 September 2021
Volume
15 - 2021
Edited by
Senthil S. Gounder, Johns Hopkins University, United States
Reviewed by
Asya Makhro, University of Zurich, Switzerland; Samuel Kohtala, University of Helsinki, Finland; Kazu Nakazawa, Southern Research Institute, United States
Updates
Copyright
© 2021 Choudhury, Autry, Tolias and Krishnan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Divya Choudhury, divya.choudhury@uchospitals.edu
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.